-
Innovation Ranking
NewInnovation Ranking – TG Therapeutics Inc
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership,...
-
Product Insights
NewLikelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Non-Small Cell Lung Cancer Drug Details: TG-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Ductal Adenocarcinoma Drug Details: TG-01 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Cancer Drug Details: TG-01 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TGI-2 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Metastatic Melanoma Drug Details: TGI-2 (NM1F) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TGI-2 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Solid Tumor Drug Details: TGI-2 (NM1F) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TGI-2 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Metastatic Colorectal Cancer Drug Details: TGI-2 (NM1F) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TGI-2 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Metastatic Ovarian Cancer Drug Details: TGI-2 (NM1F) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TGI-2 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Triple-Negative Breast Cancer (TNBC) Drug Details: TGI-2...